Abstract
Cystic fibrosis (CF) is due to mutations in the CFTR gene, which prevents correct folding, trafficking and function of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein. The dysfunctional effect of CFTR mutations, principally the F508del-CFTR mutant, is further manifested by hypersecretion of the pro-inflammatory chemokine interleukin-8 into the airway lumen, which further contributes to morbidity and mortality. We have hypothesized that microRNA (miR)-based therapeutics could rescue the dysfunctional consequences of mutant CFTR. Here we report that a miR-16 mimic can effectively rescue F508del-CFTR protein function in airway cell lines and primary cultures, of differentiated human bronchial epithelia from F508del homozygotes, which express mutant CFTR endogenously. We also identify two other miRs, miR-1 and miR-302a, which are also active. Although miR-16 is expressed at basal comparable levels in CF and control cells, miR-1 and miR-302a are undetectable. When miR mimics are expressed in CF lung or pancreatic cells, the expression of the F508del-CFTR protein is significantly increased. Importantly, miR-16 promotes functional rescue of the cyclic AMP-activated apical F508del-CFTR chloride channel in primary lung epithelial cells from CF patients. We interpret these findings to suggest that these miRs may constitute novel targets for CF therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066–1073.
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059–1065.
Bobadilla JL, Macek Jr M, Fine JP, Farrell PM . Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575–606.
Welsh MJ, Denning GM, Ostedgaard LS, Anderson MP . Dysfunction of CFTR bearing the delta F508 mutation. J Cell Sci 1993; 17: 235–239.
Dean TP, Dai Y, Shute JK, Church MK, Warner JO . Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 1993; 34: 159–161.
Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197–1204.
Dhooghe B, Noel S, Huaux F, Leal T . Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem 2014; 47: 539–546.
Elizur A, Cannon CL, Ferkol TW . Airway inflammation in cystic fibrosis. Chest 2008; 133: 489–495.
Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ . Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761–764.
Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825–18830.
Arispe N, Ma J, Jacobson KA, Pollard HB . Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 1998; 273: 5727–5734.
Caohuy H, Yang Q, Eudy Y, Ha TA, Xu AE, Glover M et al. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of DeltaF508-cystic fibrosis transmembrane conductance regulator (DeltaF508-CFTR). J Biol Chem 2014; 289: 35953–35968.
Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108: 18843–18848.
van Rij RP, Andino R . The silent treatment: RNAi as a defense against virus infection in mammals. Trends Biotechnol 2006; 24: 186–193.
Gorman C, Maron DF . The RNA revolution. Sci Am 2014; 310: 52–59.
Ghildiyal M, Zamore PD . Small silencing RNAs: an expanding universe. Nat Rev Genet 2009; 10: 94–108.
Oglesby IK, Bray IM, Chotirmall SH, Stallings RL, O'Neill SJ, McElvaney NG et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol 2010; 184: 1702–1709.
Bhattacharyya S, Balakathiresan NS, Dalgard C, Gutti U, Armistead D, Jozwik C et al. Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem 2011; 286: 11604–11615.
Ramachandran S, Karp PH, Jiang P, Ostedgaard LS, Walz AE, Fisher JT et al. A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 2012; 109: 13362–13367.
Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA 1990; 87: 4012–4016.
Sorscher E, Hong JS, Hutt DM, Chalfunt M, Roth DM, Balch WE et al. Screening of candidate adenovirus vectors expressing shRNAs for functional recovery of DeltaF508 CFTR. 24th Annual North American Cystic Fibrosis Conference; 21–23 October 2010; Pediatric Pulmonology: Baltimore, MD, USA.
Eidelman O, Srivastava M, Zhang J, Leighton X, Murtie J, Jozwik C et al. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway. Mol Med 2001; 7: 523–534.
Caohuy H, Jozwik C, Pollard HB . Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2 signaling pathway. J Biol Chem 2009; 284: 25241–25253.
Balakathiresan NS, Bhattacharyya S, Gutti U, Long RP, Jozwik C, Huang W et al. Tristetraprolin regulates IL-8 mRNA stability in cystic fibrosis lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 296: L1012–L1018.
Bhattacharyya S, Kumar P, Tsuchiya M, Bhattacharyya A, Biswas R . Regulation of miR-155 biogenesis in cystic fibrosis lung epithelial cells: antagonistic role of two mRNA-destabilizing proteins, KSRP and TTP. Biochem Biophys Res Commun 2013; 433: 484–488.
Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797–1807.
Bhattacharyya S, Gutti U, Mercado J, Moore C, Pollard HB, Biswas R . MAPK signaling pathways regulate IL-8 mRNA stability and IL-8 protein expression in cystic fibrosis lung epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2011; 300: L81–L87.
Drumm ML, Pope HA, Cliff WH, Rommens JM, Marvin SA, Tsui LC et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990; 62: 1227–1233.
Holleran JP, Glover ML, Peters KW, Bertrand CA, Watkins SC, Jarvik JW et al. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol Med 2012; 18: 685–696.
Devor DC, Bridges RJ, Pilewski JM . Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am J Physiol Cell Physiol 2000; 279: C461–C479.
Myerburg MM, King JD Jr., Oyster NM, Fitch AC, Magill A, Baty CJ et al. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 2010; 42: 676–684.
Acknowledgements
We thank Dr Cara Olsen (Biostatistician, USUHS) for helping with statistical analyses. This study was supported by USU-Intramural Funds (RB); NIH grants DK072506 and DK068196 (RAF); and Cystic Fibrosis Foundation (RB, HBP and RAF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kumar, P., Bhattacharyya, S., Peters, K. et al. miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells. Gene Ther 22, 908–916 (2015). https://doi.org/10.1038/gt.2015.56
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2015.56
This article is cited by
-
Targeted quantitation of CFTR protein expression in vivo using immunoprecipitation & parallel reaction monitoring tandem mass spectrometry
Translational Medicine Communications (2022)
-
SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
Scientific Reports (2021)
-
Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue
Scientific Reports (2020)